Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹94.80
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹482.76M
Enterprise Value₹1.39B
Total Cash (Recent Filing)₹96.75M
Total Debt (Recent Filing)₹949.21M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.84
Price to Sales (P/S)0.39
P/FCF Ratio5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable Leverage / Balanced Balance SheetA balanced debt-to-equity and adequate equity position provide structural financial stability. Manageable leverage helps absorb revenue volatility, preserves access to credit, and supports capital allocation over the medium term without forcing immediate deleveraging or asset sales.
Improving Operating Cash GenerationImproved operating cash flow indicates the core manufacturing business is generating cash from operations, supporting working capital and near-term capex. Sustained OCF strength reduces reliance on external financing and underpins medium-term operational resilience.
Specialty Chemicals And API B2B Business ModelA focus on specialty chemicals and APIs targets higher-value, regulatory-linked demand from pharma and chemicals. This B2B model typically yields durable customer relationships, quality/ compliance barriers to entry, and exposure to structural pharma outsourcing trends over months to years.
Bears Say
Declining Revenue And Contracting MarginsFalling revenue and squeezed EBIT/EBITDA margins signal weakening commercial performance or pricing pressure. Persisting contraction undermines earnings power, reduces internal funding for R&D/capex, and can erode competitive position if not reversed over the medium term.
Inconsistent And Negative Free Cash Flow PeriodsIntermittent negative free cash flow limits the company's ability to consistently invest, pay down debt, or return capital. Over time, unreliable FCF increases dependence on external funding and raises execution risk for strategic growth or quality/compliance investments.
Rising Total Debt Amid Weaker RevenuesAn upward trend in total debt while sales fall creates leverage risk: higher interest and principal obligations reduce financial flexibility. If top-line weakness continues, servicing and refinancing risks could pressure margins and force defensive measures that hurt long-term competitiveness.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹94.80 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹482.76M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is May 27, 2026 which is in 48 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on Jan 15, 2026. The company reported -₹6.214 earnings per share for the quarter, missing the consensus estimate of N/A by -₹6.214.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹6.214 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.
Technical Analysis
Bhageria Industries Ltd.
―
Ganesh Benzoplast Limited
―
HP Adhesives Ltd.
―
Khaitan Chemicals & Fertilizers Ltd.
―
Mangalam Organics Ltd
―